Literature DB >> 9161625

Adverse drug reactions in home care patients receiving nafcillin or oxacillin.

A F Dahlgren1.   

Abstract

Documented adverse reactions to anti-infective agents in patients of a home infusion company were studied to determine whether the prevalence of reactions was greater in patients receiving nafcillin or oxacillin than in those receiving other i.v. antiinfectives. Data on adverse drug reactions (ADRs) were obtained by reviewing the discharge summaries of all patients who received anti-infective therapy in 1990-1994 and the company's quarterly and annual ADR reports for that period. The occurrence of ADRs per total courses of therapy was calculated for groups of antiinfectives, as were intensity and causality. For ADRs to nafcillin and oxacillin, patient demographics and treatment information and outcomes were reviewed. A total of 2488 courses of anti-infective therapy were documented, and ADRs occurred in 10.9%. Nafcillin and oxacillin accounted for 105 courses, with an ADR rate of 31.4%; 99 patients received one of these drugs and 24 had ADRs, with rash and phlebitis the most common ADRs. Thirty-nine patients receiving nafcillin or oxacillin had documented infection with methicillin-sensitive Staphylococcus aureus. Seventy-five patients receiving nafcillin or oxacillin did not have an ADR; therapy was successful in 62 of these patients. Of the 24 patients with ADRs to nafcillin or oxacillin, 13 were switched to other i.v. anti-infectives, which were successful in 10 of them. Five patients were hospitalized because of ADRs to nafcillin or oxacillin. Most nafcillin or oxacillin ADRs that resulted in a therapy change or hospitalization occurred in the second or third week of therapy. Home care patients who received nafcillin or oxacillin therapy had a disproportionately high number of ADRs, compared with patients who received other anti-infective agents.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9161625     DOI: 10.1093/ajhp/54.10.1176

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  7 in total

1.  Tolerability of cefazolin after immune-mediated hypersensitivity reactions to nafcillin in the outpatient setting.

Authors:  Kimberly G Blumenthal; Ilan Youngster; Erica S Shenoy; Aleena Banerji; Sandra B Nelson
Journal:  Antimicrob Agents Chemother       Date:  2014-03-17       Impact factor: 5.191

2.  Comparison of Clinical Outcomes for Glycopeptides and Beta-Lactams in Methicillin-Susceptible Staphylococcus Aureus Bloodstream Infections.

Authors:  Yeon Ju La; Hye Rim Kim; Dong Hyun Oh; Jin Young Ahn; Yong Chan Kim
Journal:  Yonsei Med J       Date:  2022-07       Impact factor: 3.052

3.  Comparison of cefazolin versus oxacillin for treatment of complicated bacteremia caused by methicillin-susceptible Staphylococcus aureus.

Authors:  Julius Li; Kelly L Echevarria; Darrel W Hughes; Jose A Cadena; Jason E Bowling; James S Lewis
Journal:  Antimicrob Agents Chemother       Date:  2014-06-16       Impact factor: 5.191

Review 4.  Meta-analysis of trials comparing cefazolin to antistaphylococcal penicillins in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia.

Authors:  Joseph P Rindone; Chadwick K Mellen
Journal:  Br J Clin Pharmacol       Date:  2018-04-10       Impact factor: 4.335

5.  Prevalence of a Cefazolin Inoculum Effect Associated with blaZ Gene Types among Methicillin-Susceptible Staphylococcus aureus Isolates from Four Major Medical Centers in Chicago.

Authors:  Sheila K Wang; Annette Gilchrist; Anastasia Loukitcheva; Balbina J Plotkin; Ira M Sigar; Alan E Gross; J Nicholas O'Donnell; Natasha Pettit; Amy Buros; Tristan O'Driscoll; Nathaniel J Rhodes; Cindy Bethel; John Segreti; Angella Charnot-Katsikas; Kamaljit Singh; Marc H Scheetz
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

6.  Morbidity from in-hospital complications is greater than treatment failure in patients with Staphylococcus aureus bacteraemia.

Authors:  Natasha E Holmes; J Owen Robinson; Sebastiaan J van Hal; Wendy J Munckhof; Eugene Athan; Tony M Korman; Allen C Cheng; John D Turnidge; Paul D R Johnson; Benjamin P Howden
Journal:  BMC Infect Dis       Date:  2018-03-05       Impact factor: 3.090

7.  Community-based outpatient parenteral antimicrobial therapy (CoPAT) for Staphylococcus aureus bacteraemia with or without infective endocarditis: analysis of the randomized trial comparing daptomycin with standard therapy.

Authors:  Susan Rehm; Marilyn Campion; David E Katz; Rene Russo; Helen W Boucher
Journal:  J Antimicrob Chemother       Date:  2009-03-05       Impact factor: 5.790

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.